2015年至2023年芬兰≥20岁成人带状疱疹发病率:一项基于人群的登记研究

IF 7.8 2区 医学 Q1 INFECTIOUS DISEASES
Aapo Juutinen, Heini Salo, Toni Lehtonen, Tuija Leino
{"title":"2015年至2023年芬兰≥20岁成人带状疱疹发病率:一项基于人群的登记研究","authors":"Aapo Juutinen, Heini Salo, Toni Lehtonen, Tuija Leino","doi":"10.2807/1560-7917.ES.2025.30.35.2500077","DOIUrl":null,"url":null,"abstract":"<p><p>BACKGROUNDHerpes zoster, also known as shingles, is a painful skin condition caused by varicella zoster virus. Information is lacking on incidence of herpes zoster in Finland.AIMTo estimate age-specific annual incidence of herpes zoster over 9 years with data from several nationwide health registers.METHODSIn a nationwide study, we compiled a dataset encompassing the entire Finnish population by linking data from multiple population-based registers for 2015-23. The dataset includes records from nearly all healthcare providers in Finland. Case definitions were based on ICD-10 codes B02 and G53.0, and ICPC-2 code S70. The dataset was supplemented with information on the purchase of prescribed antiviral medication.RESULTSIn total, 220,693 herpes zoster cases were identified during 2015-23 among adults aged ≥ 20 years. In 2023, when register coverage was best, age-specific annual incidence rates for the entire population varied from 3.8 to 12.2, increasing with age. Incidence was higher among females than males, and highest among elderly aged ≥ 85 years living at home without organised care. Cumulative incidence data from 2023 revealed that lifetime risk of developing herpes zoster by age 85 was 42%, and as high as 46% using the incidence among elderly living at home without organised care.CONCLUSIONHerpes zoster incidence varied by sex and age group, and appeared to be under-reported in institutional and organised care settings. Currently, there is no official decision on herpes zoster vaccination in Finland, despite favourable recommendations from the national expert group and the National Advisory Committee on Vaccination.</p>","PeriodicalId":12161,"journal":{"name":"Eurosurveillance","volume":"30 35","pages":""},"PeriodicalIF":7.8000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12413605/pdf/","citationCount":"0","resultStr":"{\"title\":\"Herpes zoster incidence in adults aged ≥ 20 years in Finland, 2015 to 2023: a population-based register study.\",\"authors\":\"Aapo Juutinen, Heini Salo, Toni Lehtonen, Tuija Leino\",\"doi\":\"10.2807/1560-7917.ES.2025.30.35.2500077\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>BACKGROUNDHerpes zoster, also known as shingles, is a painful skin condition caused by varicella zoster virus. Information is lacking on incidence of herpes zoster in Finland.AIMTo estimate age-specific annual incidence of herpes zoster over 9 years with data from several nationwide health registers.METHODSIn a nationwide study, we compiled a dataset encompassing the entire Finnish population by linking data from multiple population-based registers for 2015-23. The dataset includes records from nearly all healthcare providers in Finland. Case definitions were based on ICD-10 codes B02 and G53.0, and ICPC-2 code S70. The dataset was supplemented with information on the purchase of prescribed antiviral medication.RESULTSIn total, 220,693 herpes zoster cases were identified during 2015-23 among adults aged ≥ 20 years. In 2023, when register coverage was best, age-specific annual incidence rates for the entire population varied from 3.8 to 12.2, increasing with age. Incidence was higher among females than males, and highest among elderly aged ≥ 85 years living at home without organised care. Cumulative incidence data from 2023 revealed that lifetime risk of developing herpes zoster by age 85 was 42%, and as high as 46% using the incidence among elderly living at home without organised care.CONCLUSIONHerpes zoster incidence varied by sex and age group, and appeared to be under-reported in institutional and organised care settings. Currently, there is no official decision on herpes zoster vaccination in Finland, despite favourable recommendations from the national expert group and the National Advisory Committee on Vaccination.</p>\",\"PeriodicalId\":12161,\"journal\":{\"name\":\"Eurosurveillance\",\"volume\":\"30 35\",\"pages\":\"\"},\"PeriodicalIF\":7.8000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12413605/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Eurosurveillance\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2807/1560-7917.ES.2025.30.35.2500077\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eurosurveillance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2807/1560-7917.ES.2025.30.35.2500077","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

背景:带状疱疹,也被称为带状疱疹,是由水痘带状疱疹病毒引起的一种疼痛的皮肤状况。芬兰缺乏关于带状疱疹发病率的信息。目的:根据来自多个国家卫生登记机构的数据,估计9年来带状疱疹特定年龄的年发病率。在一项全国性的研究中,我们通过链接2015-23年多个基于人口的登记册的数据,编制了一个包含整个芬兰人口的数据集。该数据集包括芬兰几乎所有医疗保健提供者的记录。病例定义基于ICD-10代码B02和G53.0, ICPC-2代码S70。该数据集还补充了购买处方抗病毒药物的信息。结果2015-23年共发现220,693例带状疱疹病例,患者年龄≥20岁。在登记覆盖率最好的2023年,整个人口的年龄特异性年发病率从3.8到12.2不等,随着年龄的增长而增加。女性的发病率高于男性,在≥85岁的无组织护理的居家老人中发病率最高。从2023年开始的累积发病率数据显示,到85岁时患带状疱疹的终生风险为42%,而在没有组织护理的家中生活的老年人中,发病率高达46%。结论带状疱疹发病率因性别和年龄组而异,在机构和有组织的护理机构中似乎报告不足。目前,尽管国家专家小组和国家疫苗接种咨询委员会提出了有利的建议,但芬兰尚未就带状疱疹疫苗接种作出正式决定。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Herpes zoster incidence in adults aged ≥ 20 years in Finland, 2015 to 2023: a population-based register study.

Herpes zoster incidence in adults aged ≥ 20 years in Finland, 2015 to 2023: a population-based register study.

Herpes zoster incidence in adults aged ≥ 20 years in Finland, 2015 to 2023: a population-based register study.

Herpes zoster incidence in adults aged ≥ 20 years in Finland, 2015 to 2023: a population-based register study.

BACKGROUNDHerpes zoster, also known as shingles, is a painful skin condition caused by varicella zoster virus. Information is lacking on incidence of herpes zoster in Finland.AIMTo estimate age-specific annual incidence of herpes zoster over 9 years with data from several nationwide health registers.METHODSIn a nationwide study, we compiled a dataset encompassing the entire Finnish population by linking data from multiple population-based registers for 2015-23. The dataset includes records from nearly all healthcare providers in Finland. Case definitions were based on ICD-10 codes B02 and G53.0, and ICPC-2 code S70. The dataset was supplemented with information on the purchase of prescribed antiviral medication.RESULTSIn total, 220,693 herpes zoster cases were identified during 2015-23 among adults aged ≥ 20 years. In 2023, when register coverage was best, age-specific annual incidence rates for the entire population varied from 3.8 to 12.2, increasing with age. Incidence was higher among females than males, and highest among elderly aged ≥ 85 years living at home without organised care. Cumulative incidence data from 2023 revealed that lifetime risk of developing herpes zoster by age 85 was 42%, and as high as 46% using the incidence among elderly living at home without organised care.CONCLUSIONHerpes zoster incidence varied by sex and age group, and appeared to be under-reported in institutional and organised care settings. Currently, there is no official decision on herpes zoster vaccination in Finland, despite favourable recommendations from the national expert group and the National Advisory Committee on Vaccination.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Eurosurveillance
Eurosurveillance INFECTIOUS DISEASES-
CiteScore
32.70
自引率
2.10%
发文量
430
审稿时长
3-8 weeks
期刊介绍: Eurosurveillance is a European peer-reviewed journal focusing on the epidemiology, surveillance, prevention, and control of communicable diseases relevant to Europe.It is a weekly online journal, with 50 issues per year published on Thursdays. The journal includes short rapid communications, in-depth research articles, surveillance reports, reviews, and perspective papers. It excels in timely publication of authoritative papers on ongoing outbreaks or other public health events. Under special circumstances when current events need to be urgently communicated to readers for rapid public health action, e-alerts can be released outside of the regular publishing schedule. Additionally, topical compilations and special issues may be provided in PDF format.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信